Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 9/20 | 0.41 |
| ▸ | HCAR3 | P49019 | 6/20 | 0.41 |
| ▸ | BACE1 | P56817 | 2/20 | 0.40 |
| ▸ | NSD2 | O96028 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | GSK3A | P49840 | 2/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3101214 | 0.78 | HCAR2 (0.56) | HCAR2HCAR3CYP1A2HSD11B1 | |
| SCHEMBL5531839 | 0.76 | HCAR2 (0.57) | HCAR2HCAR3CYP1A2 | |
| SCHEMBL3107917 | 0.76 | HCAR2 (0.72) | HCAR2HCAR3CYP1A2 | |
| SCHEMBL11414250 | 0.76 | HCAR2 (0.53) | HCAR2HCAR3CYP1A2 | |
| SCHEMBL3100362 | 0.75 | HCAR2 (0.43) | HCAR2HCAR3BACE1PGRCYP1A2 | |
| SCHEMBL5516439 | 0.74 | HCAR2 (0.59) | HCAR2HCAR3BACE1CYP1A2 | |
| SCHEMBL5515242 | 0.74 | HCAR2 (0.59) | HCAR2BACE1PGR | |
| SCHEMBL5524159 | 0.73 | TP53 (0.40) | HCAR2HCAR3CYP1A2 | |
| SCHEMBL3105600 | 0.72 | HCAR2 (0.57) | HCAR2HCAR3CYP1A2 | |
| SCHEMBL5520638 | 0.70 | HCAR2 (0.40) | HCAR2HCAR3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070093545-A1 | 4-Oxo-4,5-dihydro-furan-2-carboxylic acid derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093545-A1 | 4-Oxo-4,5-dihydro-furan-2-carboxylic acid derivatives and methods of treatment of metabolic-related disorders thereof | ABAT, G6PD, GLS2 | HCAR2 229/4885HCAR3 373/4885BACE1 3635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.